Revolution Medicines Highlights Strong 12-Month Overall Survival Rate for Lead Cancer Drug Regimen
Source: Benzinga ·

Revolution Medicines, Inc. (NASDAQ:RVMD) on Thursday reported encouraging updated results from its Phase 1/2 RMC-GI-102 open-label study of Rasonque (daraxonrasib) combined with gemcitabine and nab-paclitaxel (GnP) as a potential first-line treatment for metastatic pancreatic ade
Read the full story at Benzinga
Shared from the GodsView world desk: live wires next to a globe of flights, ships, fires, and quakes.